NeuroSense Therapeutics 9/2/2026 Earnings Report

NeuroSense Therapeutics EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.20
• Beat/Miss: N/A
• One Year Ago EPS: N/A

NeuroSense Therapeutics Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $0.27 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

NeuroSense Therapeutics Announcement Details

• Date: 9/2/2026
• Time: Before Market Opens
• Conference Call Date: N/A
• Conference Call Time: N/A

NeuroSense Therapeutics (NASDAQ:NRSNW), a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.